People · Operator
Named in public records as an officer, director or promoter · active 2018–2024 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Neurona Therapeutics, Inc | — | Biotechnology | Series D+ | $347.5M | $874.2M | 2019 |
| Nurix Therapeutics, Inc. | — | Pharma | Series D+ | $144.7M | $4.2B | 2020 |
| Escient Pharmaceuticals Inc | — | Biotechnology | Series C | $108.8M | $994.9M | 2018 |
Robert Tjian at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Tjian on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Goeddel | 2 | 10 |
| Andrew Schwab | 1 | 16 |
| LEON CHEN | 1 | 15 |
| Tim Kutzkey | 1 | 7 |
| Peter Hirth | 1 | 7 |
| Jason Hafler | 1 | 6 |
| Peter Svennilson | 1 | 4 |
| Leo - Guthart | 1 | 4 |
| Kevin Raidy | 1 | 4 |
| Marcus Boehm | 1 | 3 |
| Erica Whittaker | 1 | 3 |
| Kathleen Sereda Glaub | 1 | 3 |
| Kathleen Glaub | 1 | 3 |
| Julia Gregory | 1 | 3 |
| Peter Sereda Hirth | 1 | 2 |
| Brad Margus | 1 | 2 |
| Mark Goldsmith | 1 | 2 |
| James Stutz | 1 | 2 |
| Arthur T Sands | 1 | 2 |
| Jeff Tong | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.